Beyond Antivirals: Alternative Therapies for Long COVID DOI Creative Commons

Achilleas Livieratos,

Charalambos Gogos,

Karolina Akinosoglou

и другие.

Viruses, Год журнала: 2024, Номер 16(11), С. 1795 - 1795

Опубликована: Ноя. 19, 2024

Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) is a condition characterized by numerous lingering symptoms that persist for weeks to months following the viral illness. While treatment PASC still evolving, several therapeutic approaches beyond traditional antiviral therapies are being investigated, such as immune-modulating agents, anti-inflammatory drugs, and various supportive interventions focusing at alleviating enhancing recovery. We aimed summarize breadth available evidence, identify knowledge gaps, highlight promising non-antiviral COVID/PASC. followed framework scoping methodology mapping existing evidence from range studies, including randomized clinical trials, observational research, case series. Treatments evaluated include metformin, low-dose naltrexone (LDN), dexamethasone, statins, omega-3 fatty acids, L-arginine, emerging like intravenous immunoglobulin (IVIg) apheresis. Early findings suggest metformin has strongest particularly large phase 3 while LDN dexamethasone show potential based on studies. However, many treatments lack robust, large-scale trials. This review emphasizes need further research confirm efficacy these guide practice management.

Язык: Английский

A Machine-Learning Approach to Finding Gene Target Treatment Options for Long COVID DOI Creative Commons
Alejandro Lopez‐Rincon

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

Abstract Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), encompasses a range symptoms persisting for weeks or months after the acute phase COVID-19. These symptoms, affecting multiple organ systems, significantly impact quality life. This study employs machine-learning approach to identify gene targets treating COVID. Using datasets GSE275334, GSE270045, and GSE157103, Recursive Ensemble Feature Selection (REFS) was applied key genes associated with The highlights therapeutic potential targeting such PPP2CB, SOCS3, ARG1, IL6R, ECHS1. Clinical trials pharmacological interventions, including dual antiplatelet therapy anticoagulants, are explored their efficacy in managing COVID-19-related complications. findings suggest that machine learning can effectively biomarkers targets, offering promising avenue personalized treatment strategies COVID patients.

Язык: Английский

Процитировано

0
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of Post-COVID-19 condition in vulnerable populations DOI
Elisa Gentilotti, Lorenzo Maria Canziani,

Maria Giulia Caponcello

и другие.

Clinical Microbiology and Infection, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Beyond Antivirals: Alternative Therapies for Long COVID DOI Creative Commons

Achilleas Livieratos,

Charalambos Gogos,

Karolina Akinosoglou

и другие.

Viruses, Год журнала: 2024, Номер 16(11), С. 1795 - 1795

Опубликована: Ноя. 19, 2024

Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) is a condition characterized by numerous lingering symptoms that persist for weeks to months following the viral illness. While treatment PASC still evolving, several therapeutic approaches beyond traditional antiviral therapies are being investigated, such as immune-modulating agents, anti-inflammatory drugs, and various supportive interventions focusing at alleviating enhancing recovery. We aimed summarize breadth available evidence, identify knowledge gaps, highlight promising non-antiviral COVID/PASC. followed framework scoping methodology mapping existing evidence from range studies, including randomized clinical trials, observational research, case series. Treatments evaluated include metformin, low-dose naltrexone (LDN), dexamethasone, statins, omega-3 fatty acids, L-arginine, emerging like intravenous immunoglobulin (IVIg) apheresis. Early findings suggest metformin has strongest particularly large phase 3 while LDN dexamethasone show potential based on studies. However, many treatments lack robust, large-scale trials. This review emphasizes need further research confirm efficacy these guide practice management.

Язык: Английский

Процитировано

0